This role provides an excellent opportunity to shape and drive the fetrastobart vedotin global commercial potential and address the significant unmet needs of lung cancer patients.
Base: $214,900.00 to $358,100.00; Bonus/Equity: 22.5% bonus target and share-based long-term incentive; Benefits: Comprehensive and generous benefits and programs
Must-have
Nice-to-have
Permanent work authorization in the United States